Exipient: di H2O
SAGRA-4U is antineoplastic:
induces apoptosis in malignant cells
and is an immuno stimulant of cell medicated
For the treatment chemoresistant
malignancies (cancer), with or without viral ethiology.
SAGRA-4U upregulates the expression of the pro-apoptotic
protein Bax and downregulates the expression of the
anti-apoptotic protein bcl-2 in malignant cancer
SAGRA-4U activates the cell mediated (CD-8 ans NK cells)
immune response to malignant cells by unknown
SAGRA-4U is intended for the treatment of metastatic
malignancies. Can be administered orally, diluted with 30
cc's of water 1 hr. before morning meal. Patients with WHO
improved status may be treated via i.v. route directly,
once dayly. Treatment should be continued for 20 days and
the WHO performance status should be evaluated by a
professional health care worker or physician.
Treatment course may be repeated once monthly.
None reported by day.
Not recommended for administration in conjuction with
confentional toxic chemotherapeutic agents; during
pragnancy or lactation period.
This phytomedicine has been prescribed for You personally
in specific conditions. Do not use except on medical
Store in non-freezing conditions (0 - 30 degree C).
10 ampules/vials per package.